South Korea · Delayed Price · Currency is KRW ImmuneOncia Therapeutics Company Description
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer.
It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer.
The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy.
The company was incorporated in 2016 and is headquartered in Yongin-si, South Korea. ImmuneOncia Therapeutics, Inc. operates as a subsidiary of Yuhan Corporation.
| Country | South Korea |
| Founded | 2016 |
| Industry | Pharmaceutical Preparations |
| CEO | Heung Tae Kim |
Contact Details
Address: 25 Tapsil-ro 35beon-gil Yongin-si, 17084 South Korea | |
| Phone | 82 3 1306 8177 |
| Website | immuneoncia.com |
Stock Details
| Ticker Symbol | 424870 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Heung Tae Kim | Chief Executive Officer |